SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong quarterly earnings beat and first reported profit, driven by rapid growth in AI compute and Starlink, are driving attention; traders are also reacting to Musks ambitious revenue outlook. Bulls welcome the results, while skeptics argue that heavy AI infrastructure spending, a lofty valuation, and upcoming share unlocks may limit the stocks response.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary Q1 update, which sharply raised its revenue outlook and projected higher gross margins on AI-platform demand, is the dominant catalyst. Traders welcomed the stronger outlook but debate whether it can sustain a rebound, citing the stocks volatile pullback and lingering concerns about execution, governance, and the broader AI trade.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly report beat earnings expectations, but softer fourth-quarter guidance and a reduced advertising outlook heightened concerns about slowing growth and pressured the stock. Traders are divided between bearish views on the outlook, engagement and competition, and dip-buying based on the companys profitability and quarterly performance.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported Chinese orders for Nvidias export-compliant RTX PRO 5500 chips have traders weighing strong demand against U.S. export limits and Nvidias ability to supply the cards. The muted share-price response is fueling debate over whether AI demand can offset broader concerns about spending, financing risks, and weakness across chip stocks.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention after a sharp semiconductor-sector selloff and a volatile rebound, with traders citing JPMorgans upgrade to Neutral and improved execution while watching for earnings. Bulls also point to reported foundry customer prospects and Intels AMD AI-software collaboration, while skeptics question whether the turnaround can sustain the recovery.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Anticipation of Teslas quarterly results dominates, with traders debating pressure on margins and valuation versus possible updates on robotaxis, Optimus and AI. SpaceX merger speculation adds to the bullish chatter, though some traders say no deal is confirmed and expect a possible sell-the-news reaction.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Traders attributed NBISs rebound to strong SpaceX results and commentary they saw as evidence of continued demand for AI compute, lifting the broader neocloud group. The optimism is tempered by concerns over debt, funding needs and AI infrastructure spending, with traders divided on whether the bounce can hold.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp selloff across AI neocloud and data-center stocks amid concerns about financing, AI infrastructure returns, and possible industry consolidation. Traders are divided: some point to co-CEO Daniel Roberts comments that IRENs data centers were built with cash and to its customer contracts as reassurance, while others remain concerned about execution, delays, dilution, and the stocks weakness versus peers.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders await the 80th-death trigger for final analysis of its Phase 3 REGAL AML trial; the last disclosed count was 78, and no results announcement is confirmed. A sharp share-price rebound has fueled speculation about favorable data and a potential buyout, while some traders say the move lacks a confirmed company catalyst and stress that the trial outcome remains uncertain.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Debt and refinancing concerns, amplified by HSBCs bearish assessment, are driving debate as traders weigh further downside against a sharp rebound and potential short squeeze. Bulls point to strong AI-compute demand and reported GPU price increases, while skeptics question whether CoreWeaves backlog can offset its financing needs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results

ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.

Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide

Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide

 US futures are flat, with S&P contracts clinging to small gains and the Nasdaq slipping into the red as memory stocks slide, after a weekend of contradictory geopolitical headlines whipsawed oil...

BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300

Equity

According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.


Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...

Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?

AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Neutral Sentiment

<ul class="summary-bullets"><li>JPMorgan highlighted litifilimab’s development for cutaneous lupus erythematosus, a condition with no currently approved targeted therapies.</li><li>Last week, UBS raised its Biogen price target to $270 from $240 while maintaining 'Buy', while RBC Capital lowered its target to $256 from $260 and maintained 'Outperform', according to The Fly.</li><li>Biogen is scheduled to report its third-quarter 2026 results on October 28, with analysts expecting earnings of $2.66 per share and revenue of approximately $2.65 billion, according to FiscalAI.&nbsp;</li></ul><p>Shares of Biogen(BIIB) were in focus on Monday after JPMorgan upgraded the stock to an ‘Overweight’ rating from ‘Neutral’ rating and raised its price target to $300 from $210.</p><p>According to The Fly, the firm cited an increasingly compelling pipeline catalyst outlook and improved long-term growth prospects as the company approaches several clinical readouts in 2027.</p><p><a href="https://stocktwits.com/symbol/BIIB">Biogen shares</a> were trading 3.2% higher in premarket trading on Monday at $232.95, putting the stock on track to reach its highest level since July 2024, a more than two-year high.</p><h2 class="st-heading-2">What Are The Clinical Catalysts To Watch?</h2><p>JPMorgan highlighted two investigational treatments in Biogen's pipeline: felzartamab for antibody-mediated rejection and litifilimab for cutaneous lupus erythematosus. The firm identified felzartamab as a potential opportunity worth more than $2 billion and noted that no therapies are currently approved for cutaneous lupus erythematosus, according to The Fly.</p><p>Biogen's second-quarter 2026 materials listed Phase 3 readouts for both programs among the clinical milestones expected in 2027.</p><h2 class="st-heading-2">Why JPMorgan Mentioned Leqembi</h2><p>Leqembi is Biogen's Alzheimer's disease treatment, developed in collaboration with Eisai. Biogen reported global in-market sales of $184 million for Leqembi in the second quarter of 2026, up 15% year over year. U.S. in-market sales were $97 million.&nbsp;</p><p>JPMorgan said Biogen was evolving beyond “just a Leqembi story,” referring to the company's broader business and pipeline in its assessment of the stock.</p><h2 class="st-heading-2">What Have Other Analysts Said?</h2><p>JPMorgan’s upgrade follows price-target adjustments from UBS and RBC Capital last week, according to The Fly.</p><p>On Friday, October 9, UBS raised its price target on Biogen to $270 from $240 while maintaining a Buy rating. The adjustment came as part of the firm's Q3 earnings preview for U.S. pharmaceutical and large-cap biotech companies, according to The Fly.</p><p>On Thursday, October 8, RBC Capital lowered its price target to $256 from $260 while maintaining an Outperform rating. In its broader biotech earnings preview, RBC said the quarter was shaping up reasonably well for large-cap companies, helped partly by additional selling days and mid-year price increases.</p><p>RBC added that quarterly performance alone might not fully reverse sentiment toward commercial mid-cap biotech companies, although it “may help restore confidence in select stories,” according to The Fly.</p><h2 class="st-heading-2">When Is Biogen Reporting Q3 2026 Earnings?</h2><p>Biogen is scheduled to report its third-quarter 2026 financial results on Wednesday, October 28, before the market opens.</p><p>Analysts expect earnings of $2.66 per share and revenue of approximately $2.65 billion, according to FiscalAI.&nbsp;</p><h2 class="st-heading-2">How Retail Views BIIB?</h2><p>Retail sentiment on Stocktwits remained ‘neutral,’ while message volume was ‘high’ over the past 24 hours.</p><p>Biogen shares have gained more than 27% year-to-date.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bmnr-stock-gains-with-ethereum-outpacing-bitcoin-after-84-k-bounce/cZxIe9tRBFw"><strong>BMNR Stock Gains With Ethereum Outpacing Bitcoin After $84K Bounce Ahead Of CPI Report This Week</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Medical bottles and syringe are seen with Biogen logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Shares of Biogen(BIIB) were in focus on Monday after JPMorgan upgraded the stock to an ‘Overweight’ rating from ‘Neutral’ rating and raised its price target to $300 from $210.

Biogen Is More Than ‘A Leqembi Story,’ Says Analyst – Flags Two Other Drug Candidates That Could Change Its Growth Story

Track BIIB stock price, charts, news and real-time market activity on Stocktwits. Join the BIIB message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Biogen Inc stock.

BIIB Stock Price Today - Biogen Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIIB News